title: Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
abstract: Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.
authors.affiliation: Cardiology, Heart Failure and Heart Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Gori
authors.affiliation: Cardiology Department, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Volterrani
authors.affiliation: Heart Failure Unit, Cardiology Dept., Guglielmo da Saliceto Hospital, Piacenza, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Piepoli
authors.affiliation: Cardiology, Heart Failure and Heart Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. Electronic address: msenni@hpg23.it.
authors.forename: Michele
authors.initials: M
authors.lastname: Senni
mesh_terms: D000613:Aminobutyrates / Q000494:pharmacology / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002986:Clinical Trials as Topic / Q000379:methods; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D047228:Angiotensin II Type 1 Receptor Blockers; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination
keywords: ARNi; Angiotensin receptor–neprilysin inhibitor; Heart failure; LCZ696